Augustine Asset Management Inc. lowered its position in shares of Novartis AG (NYSE:NVS) by 36.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,460 shares of the company’s stock after selling 3,102 shares during the period. Augustine Asset Management Inc.’s holdings in Novartis were worth $458,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently made changes to their positions in NVS. WFG Advisors LP increased its position in shares of Novartis by 38.1% during the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after acquiring an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Novartis during the third quarter valued at approximately $106,000. Cable Hill Partners LLC increased its position in shares of Novartis by 588.8% during the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after acquiring an additional 1,107 shares in the last quarter. Harding Loevner LP bought a new stake in shares of Novartis during the second quarter valued at approximately $146,000. Finally, Sawyer & Company Inc bought a new stake in shares of Novartis during the fourth quarter valued at approximately $183,000. 10.85% of the stock is owned by institutional investors.
Shares of Novartis AG (NYSE:NVS) traded up $0.53 during mid-day trading on Monday, reaching $86.94. 770,400 shares of the company traded hands, compared to its average volume of 1,047,900. Novartis AG has a 52 week low of $69.53 and a 52 week high of $87.29. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $226,910.00, a PE ratio of 30.94, a P/E/G ratio of 2.33 and a beta of 0.74.
Several brokerages recently weighed in on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Thursday. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Leerink Swann raised their price target on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Zacks Investment Research downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Friday, October 6th. Finally, Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $85.32.
ILLEGAL ACTIVITY WARNING: This article was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://weekherald.com/2018/01/22/augustine-asset-management-inc-has-458000-holdings-in-novartis-ag-nvs.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.